FREMONT, Calif., Feb. 9, 2015 /PRNewswire/ -- Ardelyx,
Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company
focused on cardio-renal, gastrointestinal, and metabolic diseases,
today announced that Mike Raab,
President and Chief Executive Officer and David Rosenbaum Ph.D.,
Senior Vice President, Drug Development, will present a company
overview at the 2015 Leerink Global Healthcare Conference at
8:05 a.m. EST on February 12, 2015 at the Waldorf Astoria in
New York City.
The analyst-led fireside chat will be available through a live
audio webcast accessible through a link in the Investor Relations
section of the Ardelyx website at ir.ardelyx.com. A replay of
the webcast will be available for 90 days at the site after the
presentation.
About Ardelyx, Inc.
Ardelyx is a clinical-stage biopharmaceutical company focused on
the discovery, development and commercialization of innovative,
non-systemic, small molecule therapeutics that work exclusively in
the gastrointestinal tract to treat cardio-renal, gastrointestinal
and metabolic diseases. The Company has developed a proprietary
drug discovery and design platform enabling it, in a rapid and
cost-efficient manner, to discover and design novel drug
candidates. Utilizing this platform, Ardelyx has discovered and
designed tenapanor.
Ardelyx formed a collaborative partnership with AstraZeneca in
October 2012 to develop and
commercialize tenapanor. In addition to tenapanor, the Company has
discovered small molecule NaP2b inhibitors for the treatment of
hyperphosphatemia in CKD-5D, a program licensed to Sanofi, and
independently is advancing several additional research programs
focused in cardio-renal, gastrointestinal and metabolic diseases.
Ardelyx is located in Fremont,
California. For more information, please visit Ardelyx's
website at www.ardelyx.com.
Logo -
http://photos.prnewswire.com/prnh/20140619/119451
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ardelyx-to-present-at-the-2015-leerink-global-healthcare-conference-300032667.html
SOURCE Ardelyx, Inc.